PDT Partners LLC Raises Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

PDT Partners LLC raised its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 382.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 84,062 shares of the biopharmaceutical company’s stock after purchasing an additional 66,647 shares during the quarter. PDT Partners LLC owned 0.07% of Halozyme Therapeutics worth $4,019,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Smartleaf Asset Management LLC grew its stake in shares of Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 197 shares during the period. Louisiana State Employees Retirement System grew its stake in shares of Halozyme Therapeutics by 0.6% during the 4th quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company’s stock valued at $1,688,000 after acquiring an additional 200 shares during the period. CreativeOne Wealth LLC grew its stake in shares of Halozyme Therapeutics by 1.6% during the 4th quarter. CreativeOne Wealth LLC now owns 18,383 shares of the biopharmaceutical company’s stock valued at $879,000 after acquiring an additional 294 shares during the period. State of New Jersey Common Pension Fund D grew its stake in shares of Halozyme Therapeutics by 0.6% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company’s stock valued at $2,279,000 after acquiring an additional 302 shares during the period. Finally, Parkside Financial Bank & Trust grew its stake in shares of Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 322 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $60.57 on Tuesday. The stock’s fifty day moving average is $60.56 and its 200 day moving average is $55.20. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.97 and a fifty-two week high of $66.00. The firm has a market capitalization of $7.48 billion, a PE ratio of 17.66, a PEG ratio of 0.42 and a beta of 1.32. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. On average, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on HALO. Wells Fargo & Company cut their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Benchmark restated a “buy” rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. HC Wainwright restated a “buy” rating and issued a $72.00 price target on shares of Halozyme Therapeutics in a research note on Friday. Piper Sandler upped their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Finally, JPMorgan Chase & Co. upped their price target on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a “neutral” rating in a research note on Monday, April 21st. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $62.89.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the sale, the senior vice president now directly owns 185,453 shares of the company’s stock, valued at $10,765,546.65. The trade was a 5.12 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $58.69, for a total transaction of $293,450.00. Following the completion of the sale, the director now directly owns 33,611 shares of the company’s stock, valued at approximately $1,972,629.59. This trade represents a 12.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 26,697 shares of company stock worth $1,558,052. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.